U.S. Prevents Cuba from Producing Around 300 Medications

The president of the BioCubaFarma Business Group, Mayda Mauri, denounced that this industry is suffering the impact of the economic, commercial, and financial blockade imposed by Washington for more than six decades like never before.

In an interview with the Cuban News Channel, Mauri explained that in the current context and in close coordination with the Ministry of Public Health, BioCubaFarma prioritizes the production of medications that directly contribute to emergency medical services and critical patient care, such as serums and hemodialysis supplies. In parallel, it consolidates its alliances and business abroad to take advantage of income obtained from the export of innovative biotechnological products, which have generated patents and enjoy great international scientific recognition.

She clarified that the industry never exports medications that are in short supply in the country.

Mauri considered cooperation with China, and more recently with Vietnam and Russia, to be decisive for the sector's development, where the first joint ventures with benefits for both sides are already established.